Business Wire

CA-G2-RISK-SOLUTIONS

27.8.2024 15:08:33 CEST | Business Wire | Press release

Share
G2 Risk Solutions Unveils Revolutionary, Single-platform Solution for Seamlessly Integrating Merchant Risk Management

G2 Risk Solutions (G2RS), the global leader in risk and compliance business intelligence, today celebrates the release of the API version of its cornerstone product, advancing its vision to simplify and optimize merchant risk management for acquiring banks and payments facilitators. Global Onboarding, an AI-powered merchant onboarding solution, helps users safely onboard new merchants quickly with highly accurate predictive risk assessments.

One solution to manage it all

Global Onboarding is the final building block in a unified solution that integrates onboarding seamlessly with G2RS monitoring products, Persistent Merchant Monitoring and Transaction Laundering Detection. For the first time, risk managers have the ability within a single platform to underwrite merchants, approve them intelligently at scale, and then usher the flow of approved merchants in and out of activities that continuously monitor for a wide variety of illegal and/or violative conduct.

“We’re thrilled to be the first to deliver an integrated solution based on our Merchant Map® and enhanced AI,” said Brian Longe, G2RS chief executive officer. “Our customers need to operate quickly and accurately to capture new merchant opportunities while also minimizing merchant portfolio risk. Speed is money, and our solution finally lets them scale up in a safe, smart way.”

Innovation to match evolution

As the e-commerce landscape expands with new online merchants and digital payment options, competition has increased. At the same time, regulations have gotten increasingly complex and punitive, and bad actors have become more sophisticated. Companies need innovation and agility to stay ahead in this ecosystem. Effective merchant onboarding is a critical step in the efficient setup of merchant clients for secure digital payment acceptance while avoiding exposure to fraud, card service rule infractions, and regulatory fines.

"The expanding e-commerce landscape presents exciting opportunities and significant challenges for the payments industry," said Rochelle Blease, G2RS president of merchant risk solutions. "Global Onboarding empowers financial institutions and other payments providers to navigate this dynamic environment confidently, acting swiftly on new business opportunities while minimizing exposure to illegal activity and non-compliance."

Combining the industry’s best resources

Global Onboarding incorporates advanced proprietary technology to enable rapid, confident merchant onboarding. The solution includes robust G2RS risk mitigation and business enablement capabilities that are unique within the payments industry, including:

  • Merchant Map®, a proprietary, industry-exclusive merchant behavior database built over 20+ years with billions of data points, all validated by G2RS expert analysts.
  • Compass Score®, a comprehensive, AI-driven score that predicts the risk of problematic merchant activity during the next 12 months. The scoring models synthesize data from the Merchant Map and additional data sources, including watchlists and sanctions registries, consumer ratings and adverse media, and risk-based insights for content compliance and operational risk.
  • Merchant lifecycle risk management, a comprehensive approach covering risk from underwriting and onboarding to ongoing monitoring and transaction laundering detection, with re-underwriting as needed for audits or investigations.

"Our global customers need tools that keep pace with the increasing complexity and growth of the industry,” said Gavin Andrews, G2RS director of product management. “The AI-powered insights, comprehensive risk evaluations, and automation-ready workflows in Global Onboarding address the critical needs for efficiency, accuracy, and smarter decision-making when onboarding merchants. This is fintech that helps payments providers more confidently scale their operations.”

To learn more, visit g2risksolutions.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240827954388/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye